Total Assets (Quarterly) Chart

Historical Total Assets (Quarterly) Data

View and export this data back to 2003. Start Trial.
Date Value
December 31, 2019 2.410B
September 30, 2019 2.266B
June 30, 2019 2.327B
March 31, 2019 2.335B
December 31, 2018 2.223B
September 30, 2018 2.382B
June 30, 2018 2.394B
March 31, 2018 2.534B
December 31, 2017 2.443B
September 30, 2017 2.296B
June 30, 2017 2.187B
March 31, 2017 2.039B
December 31, 2016 1.825B
September 30, 2016 1.867B
June 30, 2016 1.855B
March 31, 2016 1.931B
December 31, 2015 1.898B
September 30, 2015 1.816B
June 30, 2015 2.229B
March 31, 2015 2.138B
December 31, 2014 2.245B
September 30, 2014 2.178B
June 30, 2014 2.223B
March 31, 2014 2.112B
December 31, 2013 2.032B
Date Value
September 30, 2013 1.996B
June 30, 2013 1.939B
March 31, 2013 2.000B
December 31, 2012 1.941B
September 30, 2012 1.883B
June 30, 2012 1.705B
March 31, 2012 1.695B
December 31, 2011 1.448B
September 30, 2011 1.515B
June 30, 2011 1.781B
March 31, 2011 1.668B
December 31, 2010 1.594B
September 30, 2010 1.518B
June 30, 2010
March 31, 2010 1.410B
December 31, 2009 1.427B
September 30, 2009 1.273B
June 30, 2009 1.131B
March 31, 2009 787.55M
December 31, 2008 978.60M
September 30, 2008 1.215B
June 30, 2008 1.424B
March 31, 2008 1.423B
December 31, 2007 1.416B
September 30, 2007 1.460B

Total Assets Definition

Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.

Read full definition.

Total Assets (Quarterly) Range, Past 5 Years

View Total Assets (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Assets (Quarterly) Benchmarks

View Total Assets (Quarterly) Benchmarks
Start Trial
AstraZeneca PLC 114.02B
ANI Pharmaceuticals, Inc. 1.494B
Corcept Therapeutics, Inc. 888.70M
Veru, Inc. 37.03M
Avadel Pharmaceuticals Plc 199.45M